Resolutions of the Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A.
Sartorius Stedim Biotech S.A. announced a dividend of 1.26 euros per share for fiscal 2021 during its Annual General Shareholders' Meeting held on March 29, 2022. The total distributed profit amounts to 116.1 million euros, significantly increasing from 0.68 euros in the previous year. Shareholders also renewed appointments for directors, including Pascale Boissel and Joachim Kreuzburg, for three years. The company continues its growth trajectory, with a reported sales revenue of approximately 2.89 billion euros in 2021, employing over 10,400 people.
- Dividend increased to 1.26 euros per share, up from 0.68 euros, showcasing improved profitability.
- Total distributed profit of 116.1 million euros indicates strong financial performance.
- Board renewals suggest stability and confidence in leadership.
- None.
AUBAGNE, France, March 29, 2022 /PRNewswire/ -- At today's combined Annual General Shareholders' Meeting of Sartorius Stedim Biotech S.A., shareholders passed the resolution to pay a dividend of 1.26 euros per share for fiscal 2021. The total profit distributed will be 116.1 million euros. The previous year's dividend was 0.68 euros per share.
The Annual General Shareholders' Meeting has granted discharge to all directors by a large majority and approved the renewal of the appointments as Directors of Pascale Boissel, René Fáber, Lothar Kappich, Joachim Kreuzburg, and Henri Riey for a three-year term of office.
This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim Biotech shall not assume any liability for the correctness of this release. The original French press release is the legally binding version.
Press images
https://www.sartorius.com/en/company/newsroom/downloads-publications
Financial calendar
April 21, 2022 Publication of first-quarter figures (January to March 2022)
July 21, 2022 Publication of the first-half figures (January to June 2022)
October 19, 2022 Publication of nine-month figures (January to September 2022)
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2021, the company employed more than 10,400 people, and earned sales revenue of around 2.89 billion euros.
Contact
Timo Lindemann
Corporate Communications Spokesman
+49 (0)551.308.4724
timo.lindemann@sartorius.com
www.sartorius.com
Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/resolutions-of-the-annual-shareholders-meeting-of-sartorius-stedim-biotech-sa-301512945.html
SOURCE Sartorius Stedim Biotech S.A.
FAQ
What is the dividend declared by Sartorius Stedim Biotech for fiscal 2021?
When was Sartorius Stedim Biotech's Annual General Shareholders' Meeting held?
What was the total profit distributed by Sartorius Stedim Biotech in 2022?
Who were reappointed as directors of Sartorius Stedim Biotech?
What was Sartorius Stedim Biotech's sales revenue in 2021?
